Literature DB >> 30484511

Can We Consider PR Interval to Screen Patients for Cardiac Resynchronization Therapy?

Martino Martinelli Filho1.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 30484511      PMCID: PMC6248246          DOI: 10.5935/abc.20180224

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
The search for response markers to Cardiac Resynchronization Therapy (CRT) remains intensive. Currently, the main criteria for CRT indication are the QRS morphology and the absence of myocardial fibrosis.[1] The electrocardiogram remains an important tool for selecting CRT candidates, and new parameters, such as the PR interval, are interesting to discriminate the prognosis in this population. On this issue, we have a meta-analysis study[2] concluding that the presence of prolonged PR interval is a marker of poor prognosis at baseline. In clinical practice, these data may surprise clinicians. The common sense is that it is much easier to make adjustments of the atrioventricular interval to obtain the best hemodynamic response,[3] as well as to ensure a higher rate of effective atriobiventricular resynchronization.[4] The pathophysiological hypotheses that could justify this worse prognosis remain a challenge for medicine. However, a critical view of these data is needed. The question of strong clinical interest is “Can the PR interval be used as a selection criterion for CRT indication?” This doubt cannot be clarified yet, focusing on findings of this systematic review and meta-analysis. The reason is very clear: the analysis did not include a control group with prolonged PR interval in patients not undergoing CRT, to assess its actual benefit. Therefore, this meta-analysis adds scientific collaboration, but we still have much more to study!
  4 in total

1.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

Review 2.  Meta-analysis of effects of optimization of cardiac resynchronization therapy on left ventricular function, exercise capacity, and quality of life in patients with heart failure.

Authors:  Wojciech Kosmala; Thomas H Marwick
Journal:  Am J Cardiol       Date:  2013-12-25       Impact factor: 2.778

3.  Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies.

Authors:  Gaurav A Upadhyay; Niteesh K Choudhry; Angelo Auricchio; Jeremy Ruskin; Jagmeet P Singh
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

4.  Baseline Prolonged PR Interval and Outcome of Cardiac Resynchronization Therapy: A Systematic Review and Meta-analysis.

Authors:  Pattara Rattanawong; Narut Prasitlumkum; Tanawan Riangwiwat; Napatt Kanjanahattakij; Wasawat Vutthikraivit; Pakawat Chongsathidkiet; Ross J Simpson
Journal:  Arq Bras Cardiol       Date:  2018-10-11       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.